VEINS and VIVA 2026 Announce Late-Breaking Presentations

Aug. 24, 2026 — The VIVA Foundation will spotlight the latest advances in vascular medicine as 26 clinical trials are presented during The  VEINS and VIVA 2026, taking place Oct. 3-6, at Bellagio Las Vegas. The highly anticipated late-breaking presentations will provide attendees with early access to new evidence shaping the future of vascular care.

For 24 years, VIVA (Vascular InterVentional Advances) has set the benchmark for premier education and clinical excellence in peripheral vascular disease. Known for delivering the most up-to-date, practice-changing data, VIVA brings together the latest science, technological innovation, and international expertise.

The VEINS (Venous Endovascular INterventional Strategies) complements this tradition with a dedicated focus on the diagnosis, intervention, and management of venous disorders, creating a comprehensive educational experience across the full vascular spectrum.

An international, multispecialty faculty will deliver live cases, interactive workshops, and expert discussions, alongside the presentation of groundbreaking clinical trial results, providing unmatched access to the latest advances in vascular care.

Acces Full Program

The full agenda for both conferences is available at viva-foundation.org/agenda.

Clinical trial results to be presented at the VEINS and VIVA include:
 

The VEINS

Prospective Clinical Trial Evaluating Cyanoacrylate Closure in Patients With C6 Disease: Spectrum Secondary Outcomes through 24 Months — Manj Gohel, MD

Interim 6-month Results of the BERG02 Study: A Core Lab-Adjudicated Study of Percutaneous Ligation of Superficial and Perforator Veins Combined With Sclerotherapy Using a Novel Device — Steve Elias, MD

Early 30-Day Results From a Real-World Registry of the Abre Venous Stent System in Patients With Central Venous Disease — Paul Gagne, MD

Safety and Efficacy of Mechanical Thrombectomy for Patients With Deep Vein Thrombosis: Primary Results From the Prospective, Multicenter IDE BOLT Study — Patrick E. Muck, MD

Effects of Iliac Vein Stent Placement on Quality of Life in Patients With Post-Thrombotic Syndrome: 24-Month Results From the NIH-Sponsored C-TRACT Randomized Trial — Suresh Vedantham, MD

1-Year Functional Outcomes and Quality of Life for Pulmonary Embolism After Mechanical Thrombectomy of 1,000 Prospective Patients — Andrew Holden, MBChB

A Prospective Multicenter Trial of On-The-Table Mechanically Channeled Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism: Results of the Interim Analysis of 150 Participants in the RAPID-PE Study — Riyaz Bashir, MBBS, MD

Safety and Effectiveness of the Recana Thrombectomy Catheter System for the Treatment of Venous In-Stent Restenosis and Residual Vein Obstruction — Stephen Black, MD

VIVA

First Report of the 12-Month Results From the SELUTION4SFA RCT: Comparison of a Sirolimus-Eluting Balloon vs Balloon Angioplasty for the Treatment of Femoropopliteal Artery Lesions — Jay Mathews, MD, MS

Sirolimus-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease
Stefano Barco, MD, PhD

24-Month Data From the SUCCESS PTA Study: Performance of a Novel Sirolimus-Eluting Balloon in Real-World Peripheral Artery Disease Patients — Thomas Zeller, MD

PESTO-CFA Trial: Percutaneous Intervention vs Surgery for the Treatment of CFA Lesions — Thomas Zeller, MD

Real-World 6-Month Outcomes of the Esprit BTK Drug-Eluting Resorbable Scaffold in CLTI: Results From the Post-Approval Study — Brian DeRubertis, MD

Clinical Outcomes of the MOTIV Sirolimus-Eluting Resorbable Scaffold in Rutherford Category 4 Versus Rutherford Category 5 Chronic Limb-Threatening Ischemia: Subgroup Analysis From the MOTIV Pivotal Trial — Ehrin Armstrong, MD

Predictors of Major Bleeding in Acute Intermediate-Risk Pulmonary Embolism: Analysis From the HI-PEITHO Randomized Study — Michael N. Young, MD

Functional Recovery After Acute Intermediate-High Risk Pulmonary Embolism: Relationship Between 6-Minute Walk Distance and Wearable-Derived Step-Based Activity in the STORM-PE RCT — Robert Lookstein, MD, MHCDL

Safety and Effectiveness of the Laguna Thrombectomy System™ for Treatment of Pulmonary Embolism: Outcomes From the TRUST Pivotal Study — Jay Mathews, MD, MS

Montelukast Reduces Risk of Major Adverse Limb Events After Endovascular Treatment: First Results of the CADET-PAD study — Mikołaj Maga, MD, PhD

Results From Pulsatile Intravascular Lithotripsy to Open Vessels With Calcific Walls and Enhance Vascular Compliance and Remodeling for Peripheral Artery Disease (POWER PAD II) — Jon C. George, MD

Calcified Below-the-Knee Lesions Treated With the Shockwave Medical Peripheral Intravascular Lithotripsy System: Two-Year Outcomes From the DISRUPT PAD BTK II Study — Venita Chandra, MD

Adjunctive Transdermal Continuous Oxygen Therapy Accelerates Surgical Wound Healing After Lower Extremity Revascularization: A Randomized Clinical Trial — Khanjan Nagarsheth, MD, MBA

One-Year Outcomes From the PROMISE III Trial of Transcatheter Arterialization of the Deep Veins — Daniel G. Clair, MD

12-Month Outcomes for Patients with Complex PAD Conditions (Diabetes Mellitus, CTO, Long Lesions, and/or Calcified Lesions) Treated With DES From the ELEGANCE Registry — Eric A. Secemsky, MD, MSc

9-Month Outcomes of the AGILITY Trial Iliac Cohort: A Prospective, Multicenter Study on Revello™, a Low-Profile Self-Expanding Covered Stent — Sean P. Lyden, MD

PERFORMANCE II Stroke Rates Through 1 Year: A Deep Dive Into Ipsilateral and Contralateral Stroke Outcomes by Subgroups — William A. Gray, MD

Treating Chronic Limb Ischemia Patients With Atherothrombectomy: Early Real-World Evidence From the Rotarex Global XTRACT Registry — Prakash Krishnan, MD

For more information, please visit www.viva-foundation.org.